“o.itemList.length” “this.config.text.ariaShown”
“This.config.text.ariaFermé”
OTTAWA – Prime Minister Justin Trudeau said the federal government has signed agreements with two other U.S. suppliers to reserve millions of doses of its COVID-19 experimental vaccines for Canadians.
Now there are agreements for Canada to have Johnson-proven vaccines
“His recent maximum vaccine tests show promising results,” Trudeau said.”That’s why we make sure that if one of these potential vaccines succeeds, Canada and Canadians will have the doses they need.”
Vaccines are still in Phase 2 or 3 clinical trials and will not be purchased unless effective by Health Canada.
Trudeau says everyone has said Canada can have at least 88 million doses of vaccines.Some vaccines will require more than one dose to be effective.
The agreement with Novavax, a Maryland-based biotechnology company, covers up to 76 million doses of its vaccine, which is lately in Phase 2 clinical trials in the United States and Australia.This means that their protection and effectiveness are tested in a small number of people.The earliest date the vaccine could be in a position to be widely used is next spring.
The deal with Johnson
The government says some of the doses of any approved vaccine can be produced at a new bioproduction facility at the Human Health Therapeutic Research Center in Montreal.The new facility is expected to produce up to two million doses of vaccine according to the month per month.end of next summer.
This report from The Canadian Press was first published on August 31, 2020.
Mia Rabson, Canadian Press
Note to readers: this is a corrected story. An earlier edition misspelled the call of the pharmaceutical company Novavax.